Dynamic Technology Lab’s Crinetics Pharmaceuticals CRNX Stock Holding History

Dynamic Technology Lab’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-12,434	Closed	-$358K	–	893
2025 Q2	$358K	Buy	+12,434	New	+$384K	0.05%	630
2024 Q3	–	Sell	-4,919	Closed	-$220K	–	1065
2024 Q2	$220K	Buy	+4,919	New	+$227K	0.02%	771
2023 Q3	–	Sell	-10,442	Closed	-$188K	–	1012
2023 Q2	$188K	Buy	+10,442	New	+$208K	0.02%	842
2022 Q3	–	Sell	-26,071	Closed	-$486K	–	1188
2022 Q2	$486K	Buy	+26,071	New	+$520K	0.05%	592

Other funds holding CRNX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Dynamic Technology Lab's CRNX Position: Q3 2025 in Review

Dynamic Technology Lab sold out of Crinetics Pharmaceuticals (CRNX) in Q3 2025, closing a stake of 12,434 shares — an estimated $358K sold.

Dynamic Technology Lab first reported a position in CRNX in Q2 2022 and held it in 4 quarters. The position peaked at $486K in Q2 2022. 225 funds tracked by Wall St. Rank hold CRNX as of Q3 2025.

Dynamic Technology Lab reported no remaining Crinetics Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Dynamic Technology Lab sold 12,434 Crinetics Pharmaceuticals shares in Q3 2025, an estimated $358K.
Dynamic Technology Lab first reported a position in Crinetics Pharmaceuticals in Q2 2022 and held it in 4 quarters.
Dynamic Technology Lab's Crinetics Pharmaceuticals position peaked at $486K in Q2 2022.
225 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q3 2025.

Based on Dynamic Technology Lab's 13F filing for Q3 2025, filed 13 Nov 2025.